A Trial of DCB vs DES in the Treatment of de Novo Large Diameter Coronary Atherosclerotic Stenosis(LARGE ONE)

NARecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Coronary Artery Disease
Interventions
DEVICE

SeQuent® Please drug coating balloon(DCB),Firehawk family drug eluting stent(DES)

"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"

Trial Locations (1)

272000

RECRUITING

Jining Medical University Affiliated Hospital, Jining

All Listed Sponsors
lead

Shanghai MicroPort Medical (Group) Co., Ltd.

INDUSTRY

NCT05961787 - A Trial of DCB vs DES in the Treatment of de Novo Large Diameter Coronary Atherosclerotic Stenosis(LARGE ONE) | Biotech Hunter | Biotech Hunter